Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publications 2010

Original Papers

  • Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, Ott HW, Hofer S, Pluetschow A, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010; 21(10):2052-60.
  • Böll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, Naumann R. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010; 148(3):480-2.
  • Dietlein M, Börner SM, Fischer T, Hansen H, Schnell R, Zimmermanns B, Tawadros S, Eschner W, Engert A, Staak JO, Pogge von Strandmann E, Kobe C, Schicha H, Schomäcker K. Development of an iodine-131-labeled murine anti-CD30 monoclonal antibody (131I-Ki-4): in vitro studies with L540 Hodgkin cell lines, animal studies and a feasibility study for radioimmunotherapy in patients with refractory Hodgkin’s lymphoma. Nuklearmedizin 2010; 49(3): 97–105.
  • Eich HT, Diehl V, Goergen H, Lohri A, Markova J, Debus J, Ho A, Doerken B, Rank A, Grosu A-L, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Doehner H, Borchmann P, Mueller-Hermelink K, Mueller R-P, Engert A. Intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavorable Hodgkin Lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD11 trial. J Clin Oncol 2010; 28(27):4199-206. [FINAL ANALYSIS HD11]
  • Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Dobbins SE, Lightfoot T, van Leeuwen FE, Försti A, Diepstra A, Broeks A, Vijayakrishnan J, Shield L, Lake A, Montgomery D, Roman E, Engert A, von Strandmann EP, Reiners KS, Nolte IM, Smedby KE, Adami HO, Russell NS, Glimelius B, Hamilton-Dutoit S, de Bruin M, Ryder LP, Molin D, Sorensen KM, Chang ET, Taylor M, Cooke R, Hofstra R, Westers H, van Wezel T, van Eijk R, Ashworth A, Rostgaard K, Melbye M, Swerdlow AJ, Houlston RS. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet. 2010; 42(12):1126-30.
  • Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Wilborn K, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Hiddemann W, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller R-P , Diehl V. Reduced treatment intensity in patients with early stage Hodgkin lymphoma. N Engl J Med 2010; 363(7):640-52. [FINAL ANALYSIS HD10]
  • Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol. 2010; 28(13):2239-45. [Auswertung HD15 EPO]
  • Halbsguth TV, Nogová L, Mueller H, Sieniawski M, Eichenauer DA, Schober T, Nisters-Backes H, Borchmann P, Diehl V, Engert A, Josting A. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010; 116(12):2026-32.
  • Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010; 28(34):5074-80. [FINAL ANALYSIS HD-R2]

Reviews

  • Engert A: Aktuelle Therapiestrategien der Deutschen Hodgkin Studiengruppe (GHSG) Der Onkologe 2010;16: 28-34. 
  • Engert A. Therapie des Hodgkin Lymphoms in frühen Stadien. Krebsmedizin 2010; 19(3): 123-129.
  • Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v168-71. 
  • Halbsguth T, Borchmann P. Therapiestrategien für die Behandlung des Hodgkin-Lymphoms bei älteren Patienten. Der Onkologe 2010; 16: 55-62 
  • Halbsguth T, Borchmann P. Langzeitüberleben bei Hodgkin-Lymphom. Krebsmedizin 2010; 19(3): 137-143.
  • Kobe C, Dietlein M, Fuchs M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation [letter]. Leukemia Lymphma 2010; 51(3): 552 - 553. 
  • Kobe C, Dietlein M, Kriz J, Furth C, Fuchs M, Borchmann P, Engert A, Eich HT. The role of PET in Hodgkin lymphoma and its impact on radiation oncology. Expert Rev Anticancer Ther 2010; 10(9): 1419-1428.
  • Kobe C, Dietlein M. Die Positronenemissionstomografie in den Hodgkin-Lymphom-Studien der GHSG. Krebsmedizin 2010; 19(3): 117 - 122.
  • Kriz J, Müller RP, Eich HT. Lymphozytenprädominantes Hodgkin-Lymphom. Der Onkologe 2010; 16: 41-47
  • Re D, Borchmann P. Experimentelle Therapie des Hodgkin-Lymphoms. Der Onkologe 2010; 16: 968-976. 
  • Von Tresckow B, Engert A. Fortgeschrittene Stadien und Rezidive des Hodgkin Lymphoms. Krebsmedizin 2010; 19(3): 130-136.